Charles Weijer

Charles Weijer

Auto-generated profile, based on publicly available information

Charles Weijer

Department of Medicine, Western University, London, Canada

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2018 in BMJ
Verified
Journal Article
Open access
PDF file
KHKarla Hemming
Karla Hemming
MTMonica Taljaard
Monica Taljaard
JMJoanne E McKenzie
Joanne E McKenzie
RHRichard Hooper
Richard Hooper
ACAndrew Copas
Andrew Copas
JGJeremy M Grimshaw
Jeremy M Grimshaw
This report presents the Consolidated Standards of Reporting Trials (CONSORT) extension for the stepped wedge cluster randomised trial (SW-CRT). The SW-CRT involves randomisation of clusters to different sequences that dictate the order (or timing) at which each cluster will switch to the intervention condition. The statement was developed to allow for the unique characteristics of this increasingly used study design. The guideline was developed using a Delphi survey and consensus meeting; and is informed by the CONSORT statements for individual and cluster randomised trials. Reporting items along with explanations and examples are provided. We include a glossary of terms, and explore the key properties of the SW-CRT which require special consideration in their reporting.

20 November 2012 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
CWCharles Weijer
Charles Weijer
JGJeremy Grimshaw
Jeremy Grimshaw
MEMartin P. Eccles
Martin P. Eccles
AMAndrew D. McRae
Andrew D. McRae
AWAngela White
Angela White
OGOttawa Ethics of Cluster Randomized Trials Consensus Group
Ottawa Ethics of Cluster Randomized Trials Consensus Group
The Ottawa Ethics of Cluster Trials Consensus Group sets out 15 recommendations for the ethical design and conduct of cluster randomized trials.

1 January 2013 in Trials
Verified
Journal Article
Open access
PDF file
AMAndrew D McRae
Andrew D McRae
CBCarol Bennett
Carol Bennett
JBJudith Belle Brown
Judith Belle Brown
CWCharles Weijer
Charles Weijer
RBRobert Boruch
Robert Boruch
MTMonica Taljaard
Monica Taljaard
Cluster randomized trials (CRTs) pose ethical challenges for investigators and ethics committees. This study describes the views and experiences of CRT researchers with respect to: (1) ethical challenges in CRTs; (2) the ethics review process for CRTs; and (3) the need for comprehensive ethics guidelines for CRTs.

18 August 2000 in Science
Verified
Journal Article
Closed access
CWC. Weijer
C. Weijer
EEE. J. Emanuel
E. J. Emanuel
Although for the last 50 years, ethicists dealing with human experimentation have focused primarily on the need to protect individual research subjects and vulnerable groups, biomedical research, especially in genetics, now requires the establishment of standards for the protection of communities. We have developed such a strategy, based on five steps. (i) Identification of community characteristics relevant to the biomedical research setting, (ii) delineation of a typology of different types of communities using these characteristics, (iii) determination of the range of possible community protections, (iv) creation of connections between particular protections and one or more community characteristics necessary for its implementation, and (v) synthesis of community characteristics and possible protections to define protections appropriate for each type of community. Depending on the particular community, consent and consultation, consultation alone, or no added protections may be required for research.

14 July 2017 in BMJ
Verified
Journal Article
Open access
PDF file
KHK Hemming
K Hemming
SES Eldridge
S Eldridge
GFG Forbes
G Forbes
CWC Weijer
C Weijer
MTMonica Taljaard
Monica Taljaard
Cluster randomised trials have diminishing returns in power and precision as cluster size increases. Making the cluster a lot larger while keeping the number of clusters fixed might yield only a very small increase in power and precision, owing to the intracluster correlation. Identifying the point at which observations start making a negligible contribution to the power or precision of the study—which we call the point of diminishing returns—is important for designing efficient trials. Current methods for identifying this point are potentially useful as rules of thumb but don’t generally work well. We introduce several practical aids to help researchers design cluster randomised trials in which all observations make a material contribution to the study. Power curves enable identification of the point at which observations begin to make a negligible contribution to a study for a given target difference. Under this paradigm, the number needed per arm under individual randomisation gives an upper bound on the cluster size, which should not be exceeded. Corresponding precision curves can be useful for accommodating flexibility in the choice of target difference and show the point at which confidence intervals around the estimated effect size no longer decrease. To design efficient trials, the number of clusters and cluster size should be determined concurrently, not independently. Funders and researchers should be aware of diminishing returns in cluster trials. Researchers should routinely plot power or precision curves when performing sample size calculations so that the implications of cluster sizes can be transparent. Even when data appear to be “free,” in the sense that few resources are needed to obtain the data, excessive cluster sizes can have important ramifications

1 June 2004 in Nature Medicine
Verified
Journal Article
Closed access
CWCharles Weijer
Charles Weijer
PMPaul B Miller
Paul B Miller